Joe Duarte

Dr. Joe Duarte has been a professional investor and independent analyst since 1990.  He is a former Registered Investment Advisor and author of the Bestselling "Options Trading for Dummies," now in its 4th edition and several other books including "Market Timing for Dummies" and "Successful Biotech Investing". Although Joe's favorite areas of the market are technology and healthcare, he is a versatile investor who enjoys finding that hidden gem stock before the crowd, no matter what the sector. He is an original CNBC Market Maven, and is visible regularly on Stockcharts.TV. He has published articles on Marketwatch.com and has been widely quoted in the major media including The Wall Street Journal and Barron’s magazine.  

Analyst Articles

The Nasdaq Biotech Index (NBI) rallied an impressive 5.95% on April 5th.  The conventional wisdom thrown around Wall Street was that the rally came after the U.S. Treasury passed a new set of rules to prevent any more U.S. drug companies from merging with foreign companies in order to pay… Read More

The Nasdaq Biotech Index (NBI) rallied an impressive 5.95% on April 5th.  The conventional wisdom thrown around Wall Street was that the rally came after the U.S. Treasury passed a new set of rules to prevent any more U.S. drug companies from merging with foreign companies in order to pay… Read More

This morning shares of Opko Health (OPK) fell hard in pre-market trading. The company received an FDA notice that it will not receive approval for its drug, Rayaldee.  What’s important here is that the denial was not directly related to Opko, but to the company that will manufacture the drug. … Read More

This morning shares of Opko Health (OPK) fell hard in pre-market trading. The company received an FDA notice that it will not receive approval for its drug, Rayaldee.  What’s important here is that the denial was not directly related to Opko, but to the company that will manufacture the drug. … Read More

We think the market is wrong about Opko Health (OPK). It’s acquisitions have already delivered profits and operating capital, buying it now could be an excellent long-term play. We are also looking to add this company to our EBIS list in the not too distant future.Opko’s strategy of consolidating its recent acquisitions resulted… Read More

We think the market is wrong about Opko Health (OPK). It’s acquisitions have already delivered profits and operating capital, buying it now could be an excellent long-term play. We are also looking to add this company to our EBIS list in the not too distant future.Opko’s strategy of consolidating its recent acquisitions resulted… Read More

In this issue: The Big Picture: Is Biotech Dead Money? In Depth: New EBIS Pick:  Whitewave Foods (WWAV) – Food. Science. Momentum. Special Situation Trading Portfolio: Biotech ETF Short Term Trade Details Long Term Holding EBIS Portfolio:  VIVO News, Breakout – Updated Buy Range News and Analysis: Biosimilars:  Behind the… Read More

In this issue: The Big Picture: Is Biotech Dead Money? In Depth: New EBIS Pick:  Whitewave Foods (WWAV) – Food. Science. Momentum. Special Situation Trading Portfolio: Biotech ETF Short Term Trade Details Long Term Holding EBIS Portfolio:  VIVO News, Breakout – Updated Buy Range News and Analysis: Biosimilars:  Behind the… Read More

Food. Science. Momentum.In the emerging world of applied science, Whitewave Food (NYSE: WWAV), a spinoff from Dean Foods is prototypical of an emerging sector, that of applied science without the emphasis on electronic products such as phones and PCs.  The company harnesses the power of nature with its focus on… Read More

Food. Science. Momentum.In the emerging world of applied science, Whitewave Food (NYSE: WWAV), a spinoff from Dean Foods is prototypical of an emerging sector, that of applied science without the emphasis on electronic products such as phones and PCs.  The company harnesses the power of nature with its focus on… Read More